Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$7.12 USD
-0.29 (-3.91%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $7.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Enanta Pharmaceuticals, Inc.'s return on equity, or ROE, is -79.83% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that ENTA has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ENTA 7.12 -0.29(-3.91%)
Will ENTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ENTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENTA
Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?
ENTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Other News for ENTA
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration | ENTA Stock News
HC Wainwright Initiates Coverage on Enanta Pharma (ENTA) with Buy Rating | ENTA Stock News
Enanta (ENTA) Receives Buy Rating from H.C. Wainwright
Enanta assumed with a Buy at H.C. Wainwright